Key facts
- This page summarizes Xichen Lin's Form 4 filing for Structure Therapeutics Inc. (GPCR).
- 6 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 05 Jun 2024, 19:38.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Conversion of derivative security
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Conversion of derivative security
Sale
Sale
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
The Ordinary Shares were converted into American Depositary Shares as reported in Table II above.
Footnote F2
1/4 of the shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
Footnote F3
This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 106,200 Ordinary Shares.
Footnote F4
Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
Footnote F5
106,200 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 35,400 American Depositary Shares.
Footnote F6
The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on December 28, 2023.
Footnote F7
The weighted average sale price for the transaction reported was $50.004, and the range of prices were between $50.00 and $50.16. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.